United States Adrenomyeloneuropathy Treatment Market Report & Forecast 2021-2027

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

This report contains market size and forecasts of Adrenomyeloneuropathy Treatment in United States, including the following market information:
United States Adrenomyeloneuropathy Treatment Market Revenue, 2016-2021, 2022-2027, ($ millions)
United States top five Adrenomyeloneuropathy Treatment companies in 2020 (%)
The global Adrenomyeloneuropathy Treatment market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.

The United States Adrenomyeloneuropathy Treatment market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.

QYResearch has surveyed the Adrenomyeloneuropathy Treatment Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
United States Adrenomyeloneuropathy Treatment Market, By Type, 2016-2021, 2022-2027 ($ Millions)
United States Adrenomyeloneuropathy Treatment Market Segment Percentages, By Type, 2020 (%)
    Steroid Replacement Therapy
    Stem Cell Transplant

United States Adrenomyeloneuropathy Treatment Market, By Application, 2016-2021, 2022-2027 ($ Millions)
United States Adrenomyeloneuropathy Treatment Market Segment Percentages, By Application, 2020 (%)
    Hospitals
    Clinics
    Ambulatory Surgical Centers
    Others

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adrenomyeloneuropathy Treatment revenues in United States market, 2016-2021 (Estimated), ($ millions)
Key companies Adrenomyeloneuropathy Treatment revenues share in United States market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Ascend Biopharmaceuticals
    Novadip Biosciences
    Eureka Therapeutics
    Human Longevity
    Regeneus
    Allogene Therapeutics
    BioRestorative Therapies
    Immatics Biotechnologies
    NewLink Genetics
    Cytori Therapeutics
    Talaris Therapeutics

 1 Introduction to Research & Analysis Reports
    1.1 Adrenomyeloneuropathy Treatment Market Definition
    1.2 Market Segments
        1.2.1 Segment by Type
        1.2.2 Segment by Application
    1.3 United States Adrenomyeloneuropathy Treatment Market Overview
    1.4 Methodology & Sources of Information
        1.4.1 Research Methodology
        1.4.2 Research Process
        1.4.3 Base Year

 2 United States Adrenomyeloneuropathy Treatment Overall Market Size
    2.1 United States Adrenomyeloneuropathy Treatment Market Size: 2021 VS 2027
    2.2 United States Adrenomyeloneuropathy Treatment Revenue, Prospects & Forecasts: 2016-2027
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints

 3 Company Landscape
    3.1 Top Adrenomyeloneuropathy Treatment Players in United States Market
    3.2 Top United States Adrenomyeloneuropathy Treatment Companies Ranked by Revenue
    3.3 United States Adrenomyeloneuropathy Treatment Revenue by Companies
    3.4 Top 3 and Top 5 Adrenomyeloneuropathy Treatment Companies in United States Market, by Revenue in 2020
    3.5 Companies Adrenomyeloneuropathy Treatment Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Adrenomyeloneuropathy Treatment Players in United States Market
        3.6.1 List of Tier 1 Adrenomyeloneuropathy Treatment Companies in United States
        3.6.2 List of Tier 2 and Tier 3 Adrenomyeloneuropathy Treatment Companies in United States

 4 Sights by Type
    4.1 Overview
        4.1.1 By Type - United States Adrenomyeloneuropathy Treatment Market Size Markets, 2021 & 2027
        4.1.2 Steroid Replacement Therapy
        4.1.3 Stem Cell Transplant
    4.2 By Type - United States Adrenomyeloneuropathy Treatment Revenue & Forecasts
        4.2.1 By Type - United States Adrenomyeloneuropathy Treatment Revenue, 2016-2021
        4.2.2 By Type - United States Adrenomyeloneuropathy Treatment Revenue, 2022-2027
        4.2.3 By Type - United States Adrenomyeloneuropathy Treatment Revenue Market Share, 2016-2027

 5 Sights by Application
    5.1 Overview
        5.1.1 By Application - United States Adrenomyeloneuropathy Treatment Market Size, 2021 & 2027
        5.1.2 Hospitals
        5.1.3 Clinics
        5.1.4 Ambulatory Surgical Centers
        5.1.5 Others
    5.2 By Application - United States Adrenomyeloneuropathy Treatment Revenue & Forecasts
        5.2.1 By Application - United States Adrenomyeloneuropathy Treatment Revenue, 2016-2021
        5.2.2 By Application - United States Adrenomyeloneuropathy Treatment Revenue, 2022-2027
        5.2.3 By Application - United States Adrenomyeloneuropathy Treatment Revenue Market Share, 2016-2027

 6 Adrenomyeloneuropathy Treatment Companies Profiles
    6.1 Ascend Biopharmaceuticals
        6.1.1 Ascend Biopharmaceuticals Company Details
        6.1.2 Ascend Biopharmaceuticals Business Overview
        6.1.3 Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Introduction
        6.1.4 Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.1.5 Ascend Biopharmaceuticals Recent Developments
    6.2 Novadip Biosciences
        6.2.1 Novadip Biosciences Company Details
        6.2.2 Novadip Biosciences Business Overview
        6.2.3 Novadip Biosciences Adrenomyeloneuropathy Treatment Introduction
        6.2.4 Novadip Biosciences Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.2.5 Novadip Biosciences Recent Developments
    6.3 Eureka Therapeutics
        6.3.1 Eureka Therapeutics Company Details
        6.3.2 Eureka Therapeutics Business Overview
        6.3.3 Eureka Therapeutics Adrenomyeloneuropathy Treatment Introduction
        6.3.4 Eureka Therapeutics Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.3.5 Eureka Therapeutics Recent Developments
    6.4 Human Longevity
        6.4.1 Human Longevity Company Details
        6.4.2 Human Longevity Business Overview
        6.4.3 Human Longevity Adrenomyeloneuropathy Treatment Introduction
        6.4.4 Human Longevity Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.4.5 Human Longevity Recent Developments
    6.5 Regeneus
        6.5.1 Regeneus Company Details
        6.5.2 Regeneus Business Overview
        6.5.3 Regeneus Adrenomyeloneuropathy Treatment Introduction
        6.5.4 Regeneus Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.5.5 Regeneus Recent Developments
    6.6 Allogene Therapeutics
        6.6.1 Allogene Therapeutics Company Details
        6.6.2 Allogene Therapeutics Business Overview
        6.6.3 Allogene Therapeutics Adrenomyeloneuropathy Treatment Introduction
        6.6.4 Allogene Therapeutics Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.6.5 Allogene Therapeutics Recent Developments
    6.7 BioRestorative Therapies
        6.7.1 BioRestorative Therapies Company Details
        6.7.2 BioRestorative Therapies Business Overview
        6.7.3 BioRestorative Therapies Adrenomyeloneuropathy Treatment Introduction
        6.7.4 BioRestorative Therapies Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.7.5 BioRestorative Therapies Recent Developments
    6.8 Immatics Biotechnologies
        6.8.1 Immatics Biotechnologies Company Details
        6.8.2 Immatics Biotechnologies Business Overview
        6.8.3 Immatics Biotechnologies Adrenomyeloneuropathy Treatment Introduction
        6.8.4 Immatics Biotechnologies Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.8.5 Immatics Biotechnologies Recent Developments
    6.9 NewLink Genetics
        6.9.1 NewLink Genetics Company Details
        6.9.2 NewLink Genetics Business Overview
        6.9.3 NewLink Genetics Adrenomyeloneuropathy Treatment Introduction
        6.9.4 NewLink Genetics Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.9.5 NewLink Genetics Recent Developments
    6.10 Cytori Therapeutics
        6.10.1 Cytori Therapeutics Company Details
        6.10.2 Cytori Therapeutics Business Overview
        6.10.3 Cytori Therapeutics Adrenomyeloneuropathy Treatment Introduction
        6.10.4 Cytori Therapeutics Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.10.5 Cytori Therapeutics Recent Developments
    6.11 Talaris Therapeutics
        6.11.1 Talaris Therapeutics Company Details
        6.11.2 Talaris Therapeutics Business Overview
        6.11.3 Talaris Therapeutics Adrenomyeloneuropathy Treatment Introduction
        6.11.4 Talaris Therapeutics Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021)
        6.11.5 Talaris Therapeutics Recent Developments

 7 Conclusion

 8 Appendix
    8.1 Note
    8.2 Examples of Clients
    8.3 Author Details
    8.4 Disclaimer

List of Tables
    Table 1. Adrenomyeloneuropathy Treatment Market Opportunities & Trends in United States Market
    Table 2. Adrenomyeloneuropathy Treatment Market Drivers in United States Market
    Table 3. Adrenomyeloneuropathy Treatment Market Restraints in United States Market
    Table 4. Key Players of Adrenomyeloneuropathy Treatment in United States Market
    Table 5. Top Adrenomyeloneuropathy Treatment Players in United States Market, Ranking by Revenue (2019)
    Table 6. United States Adrenomyeloneuropathy Treatment Revenue by Companies, (US$, Mn), 2016-2021
    Table 7. United States Adrenomyeloneuropathy Treatment Revenue Share by Companies, 2016-2021
    Table 8. Companies Adrenomyeloneuropathy Treatment Product Type
    Table 9. List of Tier 1 Adrenomyeloneuropathy Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
    Table 10. List of Tier 2 and Tier 3 Adrenomyeloneuropathy Treatment Companies, Revenue (US$, Mn) in 2020 and Market Share
    Table 11. By Type – United States Adrenomyeloneuropathy Treatment Revenue, (US$, Mn), 2021 & 2027
    Table 12. By Type - United States Adrenomyeloneuropathy Treatment Revenue (US$, Mn), 2016-2021
    Table 13. By Type - United States Adrenomyeloneuropathy Treatment Revenue (US$, Mn), 2022-2027
    Table 14. By Application – United States Adrenomyeloneuropathy Treatment Revenue, (US$, Mn), 2021 VS 2027
    Table 15. By Application - United States Adrenomyeloneuropathy Treatment Revenue (US$, Mn), 2016-2021
    Table 16. By Application - United States Adrenomyeloneuropathy Treatment Revenue (US$, Mn), 2022-2027
    Table 17. Ascend Biopharmaceuticals Company Details
    Table 18. Ascend Biopharmaceuticals Business Overview
    Table 19. Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Product
    Table 20. Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 21. Ascend Biopharmaceuticals Recent Developments
    Table 22. Novadip Biosciences Company Details
    Table 23. Novadip Biosciences Business Overview
    Table 24. Novadip Biosciences Adrenomyeloneuropathy Treatment Product
    Table 25. Novadip Biosciences Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 26. Novadip Biosciences Recent Developments
    Table 27. Eureka Therapeutics Company Details
    Table 28. Eureka Therapeutics Business Overview
    Table 29. Eureka Therapeutics Adrenomyeloneuropathy Treatment Product
    Table 30. Eureka Therapeutics Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 31. Eureka Therapeutics Recent Developments
    Table 32. Human Longevity Company Details
    Table 33. Human Longevity Business Overview
    Table 34. Human Longevity Adrenomyeloneuropathy Treatment Product
    Table 35. Human Longevity Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 36. Human Longevity Recent Developments
    Table 37. Regeneus Company Details
    Table 38. Regeneus Business Overview
    Table 39. Regeneus Adrenomyeloneuropathy Treatment Product
    Table 40. Regeneus Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 41. Regeneus Recent Developments
    Table 42. Allogene Therapeutics Company Details
    Table 43. Allogene Therapeutics Business Overview
    Table 44. Allogene Therapeutics Adrenomyeloneuropathy Treatment Product
    Table 45. Allogene Therapeutics Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 46. Allogene Therapeutics Recent Developments
    Table 47. BioRestorative Therapies Company Details
    Table 48. BioRestorative Therapies Business Overview
    Table 49. BioRestorative Therapies Adrenomyeloneuropathy Treatment Product
    Table 50. BioRestorative Therapies Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 51. BioRestorative Therapies Recent Developments
    Table 52. Immatics Biotechnologies Company Details
    Table 53. Immatics Biotechnologies Business Overview
    Table 54. Immatics Biotechnologies Adrenomyeloneuropathy Treatment Product
    Table 55. Immatics Biotechnologies Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 56. Immatics Biotechnologies Recent Developments
    Table 57. NewLink Genetics Company Details
    Table 58. NewLink Genetics Business Overview
    Table 59. NewLink Genetics Adrenomyeloneuropathy Treatment Product
    Table 60. NewLink Genetics Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 61. NewLink Genetics Recent Developments
    Table 62. Cytori Therapeutics Company Details
    Table 63. Cytori Therapeutics Business Overview
    Table 64. Cytori Therapeutics Adrenomyeloneuropathy Treatment Product
    Table 65. Cytori Therapeutics Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 66. Cytori Therapeutics Recent Developments
    Table 67. Talaris Therapeutics Company Details
    Table 68. Talaris Therapeutics Business Overview
    Table 69. Talaris Therapeutics Adrenomyeloneuropathy Treatment Product
    Table 70. Talaris Therapeutics Adrenomyeloneuropathy Treatment Revenue in United States Market (2016-2021) & (US$ Million)
    Table 71. Talaris Therapeutics Recent Developments
List of Figures
    Figure 1. Adrenomyeloneuropathy Treatment Segment by Type
    Figure 2. Adrenomyeloneuropathy Treatment Segment by Application
    Figure 3. United States Adrenomyeloneuropathy Treatment Market Overview: 2020
    Figure 4. United States Adrenomyeloneuropathy Treatment Market Size: 2021 VS 2027 (US$, Mn)
    Figure 5. United States Adrenomyeloneuropathy Treatment Revenue, 2016-2027 (US$, Mn)
    Figure 6. The Top 3 and 5 Players Market Share by Adrenomyeloneuropathy Treatment Revenue in 2020
    Figure 7. By Type - United States Adrenomyeloneuropathy Treatment Revenue Market Share, 2016-2027
    Figure 8. By Application - United States Adrenomyeloneuropathy Treatment Revenue Market Share, 2016-2027
    Figure 9. Ascend Biopharmaceuticals Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 10. Novadip Biosciences Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 11. Eureka Therapeutics Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 12. Human Longevity Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 13. Regeneus Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 14. Allogene Therapeutics Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 15. BioRestorative Therapies Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 16. Immatics Biotechnologies Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 17. NewLink Genetics Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 18. Cytori Therapeutics Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
    Figure 19. Talaris Therapeutics Adrenomyeloneuropathy Treatment Revenue Year Over Year Growth (US$, Mn) & (2016-2021)

This report contains market size and forecasts of Adrenomyeloneuropathy Treatment in United States, including the following market information:
United States Adrenomyeloneuropathy Treatment Market Revenue, 2016-2021, 2022-2027, ($ millions)
United States top five Adrenomyeloneuropathy Treatment companies in 2020 (%)
The global Adrenomyeloneuropathy Treatment market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.

The United States Adrenomyeloneuropathy Treatment market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.

QYResearch has surveyed the Adrenomyeloneuropathy Treatment Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
United States Adrenomyeloneuropathy Treatment Market, By Type, 2016-2021, 2022-2027 ($ Millions)
United States Adrenomyeloneuropathy Treatment Market Segment Percentages, By Type, 2020 (%)
    Steroid Replacement Therapy
    Stem Cell Transplant

United States Adrenomyeloneuropathy Treatment Market, By Application, 2016-2021, 2022-2027 ($ Millions)
United States Adrenomyeloneuropathy Treatment Market Segment Percentages, By Application, 2020 (%)
    Hospitals
    Clinics
    Ambulatory Surgical Centers
    Others

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Adrenomyeloneuropathy Treatment revenues in United States market, 2016-2021 (Estimated), ($ millions)
Key companies Adrenomyeloneuropathy Treatment revenues share in United States market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Ascend Biopharmaceuticals
    Novadip Biosciences
    Eureka Therapeutics
    Human Longevity
    Regeneus
    Allogene Therapeutics
    BioRestorative Therapies
    Immatics Biotechnologies
    NewLink Genetics
    Cytori Therapeutics
    Talaris Therapeutics